Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
Orthopedia (KIDS) is a medical device innovator focused exclusively on pediatric orthopedic solutions, developing specialized implants and surgical instruments for children's unique anatomical needs. This dedicated news hub provides investors, analysts, and healthcare professionals with centralized access to official company announcements and developments.
Find timely updates on financial earnings, product launches, regulatory milestones, and strategic partnerships that demonstrate Orthopedia's leadership in pediatric care innovation. Each press release and news article is curated to deliver actionable insights into the company's operational progress and market positioning.
As a vital resource for tracking advancements in children's orthopedic healthcare, this page offers verified information to support informed decision-making. Bookmark this hub or check back regularly for essential updates directly impacting the evolving landscape of pediatric medical technology.
OrthoPediatrics Corp. (KIDS) announced the pricing of a public offering of 750,000 shares of common stock at $55.00 per share, alongside pre-funded warrants for an additional 1,525,000 shares. The total expected gross proceeds are approximately $125 million. These funds will be used for expanding product offerings, repaying debt, supporting R&D, and enhancing sales and marketing efforts. The offering is set to close around August 15, 2022, pending customary conditions.
OrthoPediatrics Corp. (Nasdaq: KIDS) has announced an underwritten public offering of its common stock and pre-funded warrants to purchase shares. The offering, managed by Piper Sandler and Stifel, includes a 30-day option for underwriters to purchase additional shares. Proceeds will support investments in implant and instrument sets, long-term debt repayment, research and development, and sales expansion. The securities are offered under a shelf registration statement effective since March 2020, with no assurance on completion timing due to market conditions.
OrthoPediatrics Corp. (KIDS) reported a record revenue of $32.9 million for Q2 2022, marking a 23% year-over-year increase. The company helped over 23,000 children, raising the total to 560,000. Adjusted EBITDA reached $2.1 million, up from $1.2 million in Q2 2021. Revenue from Trauma & Deformity grew 26%, while Scoliosis revenue increased 23%. The company raised its full-year revenue guidance to $127-$130 million, reflecting a 30%-33% growth compared to 2021.
OrthoPediatrics Corp. (NASDAQ: KIDS) is set to release its second quarter 2022 financial results on August 3, 2022, post-market. A conference call will follow on August 4, 2022, at 8:00 a.m. ET, to discuss these results. OrthoPediatrics specializes in pediatric orthopedics, offering 39 surgical systems across trauma, scoliosis, and sports medicine categories. The company's products are marketed in the U.S. and 70 additional countries, reflecting its extensive global reach.
OrthoPediatrics Corp. (Nasdaq: KIDS) has entered into an exclusive distribution agreement with 3D-Side S.A. to distribute the 3D-CUT-OSTEO osteotomy guide in leading pediatric hospitals in the U.S. and select international markets. This innovative technology utilizes patient-specific 3D printed cutting guides, enhancing surgical precision for corrective procedures and tumor resections. OrthoPediatrics aims to complement its offerings in pediatric orthopedics by increasing its presence in the pediatric oncology market, addressing complex treatment needs.
OrthoPediatrics Corp. (KIDS) announced its acquisition of Pega Medical for $33 million, consisting of $31 million cash and $2 million in stock with restrictions. This acquisition enhances OrthoPediatrics' product offerings aimed at addressing pediatric musculoskeletal disorders. Pega's innovations, such as the Fassier-Duval Telescopic Intramedullary System™, are designed for treating conditions like Osteogenesis Imperfecta. Additionally, OrthoPediatrics raised its 2022 revenue guidance to $125-$128 million, reflecting a growth of 27%-31%.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced an agreement to acquire Pega Medical for up to $33 million, enhancing its pediatric orthopedic portfolio. The deal includes a $31 million cash payment and $2 million in stock. OrthoPediatrics plans to finance the acquisition using an expanded credit facility of $50 million. The company also raised its full-year 2022 revenue guidance to a range of $125 million to $128 million, reflecting a 27% to 31% growth. This acquisition aims to better address needs in treating children with conditions like osteogenesis imperfecta.
OrthoPediatrics Corp (Nasdaq: KIDS) will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 15, 2022, at 1:00 pm ET. The chat will feature CEO Dave Bailey and COO/CFO Fred Hite discussing advancements in pediatric orthopedics. An audio webcast will be accessible on their investor relations website, with a replay available for 90 days post-event. Founded in 2006, OrthoPediatrics focuses on pediatric orthopedic solutions, offering 37 surgical systems that cater to trauma, scoliosis, and sports medicine.
OrthoPediatrics Corp. (NASDAQ: KIDS) continues its support for the 2022 Pediatric Orthopaedic Society of North America (POSNA) annual meeting from May 11-14 in Vancouver, Canada, as a Double Diamond Sponsor. The company showcases its expanding product portfolio, including ApiFix and 7D Flash Navigation Technology through a partnership with SeaSpine. Following the acquisition of MD Orthopaedics, OrthoPediatrics aims to enhance its non-surgical offerings, particularly Ankle/Foot Orthosis (AFOs) for treating Club Foot. The event marks a return to live meetings, emphasizing OrthoPediatrics' commitment to pediatric orthopedics.
OrthoPediatrics Corp. (KIDS) reported a 9% year-over-year revenue increase for Q1 2022, generating $23.4 million compared to $21.5 million in Q1 2021. Domestic revenue grew by 8%, while international revenue rose by 13%. The company helped over 9,300 children during the quarter, reaching a total of more than 243,000 since inception. Gross profit improved by 14% to $18.6 million with a gross margin of 79.3%. Following the acquisition of MD Orthopaedics, full-year revenue guidance was raised to $122 million to $125 million.
